Atlas Trials

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Clinical trial NCT04956302 · TERMINATED

Trial details

NCT number
NCT04956302
Sponsor
Abdullah Khan
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Start date
2021-09-27
Primary completion
2022-06-16
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.